Hepatitis C Virus Infection- Pipeline Insight, 2024

Hepatitis C Virus Infection- Pipeline Insight, 2024

DelveInsight’s, “Hepatitis C Virus Infection- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatitis C Virus Infection: Understanding

Hepatitis C Virus Infection: Overview

Hepatitis C Virus Infection is a liver infection caused by the Hepatitis C Virus Infection virus. Hepatitis C Virus Infection can range from a mild illness lasting a few weeks to a serious, long-term illness. The Hepatitis C Virus Infection virus (HCV) spreads through contaminated blood. The Hepatitis C Virus Infection virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, and unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood. Hepatitis C Virus Infection is often described as “acute,” meaning a new infection, or “chronic,” meaning long-term infection. Chronic Hepatitis C Virus Infection can be a serious disease resulting in long-term health problems, including liver damage, liver failure, cirrhosis, liver cancer, and even death. Symptoms may include fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, grey-colored faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes). Treatments for Hepatitis C Virus Infection includes antivirals, like medications called direct-acting antivirals (DAAs) work to fully remove the Hepatitis C Virus Infection virus from the body while helping prevent liver damage.

""Hepatitis C Virus Infection- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis C Virus Infection pipeline landscape is provided which includes the disease overview and Hepatitis C Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Hepatitis C Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis C Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C Virus Infection.

Hepatitis C Virus Infection Emerging Drugs Chapters

This segment of the Hepatitis C Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis C Virus Infection Emerging Drugs

• TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic Hepatitis C Virus Infection virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.

• CC-31244: Cocrystal Pharma

CC-31244, a non-nucleoside polymerase inhibitor (“NNI”), is a potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. It has the potential to be an important component in an all-oral ultra-short duration HCV combination therapy. Currently the drug is Phase IIa for the treatment of viral hepatitis C.

Further product details are provided in the report……..

Hepatitis C Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis C Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatitis C Virus Infection

There are approx. 20+ key companies which are developing the therapies for Hepatitis C Virus Infection. The companies which have their Hepatitis C Virus Infection drug candidates in the most advanced stage, i.e. phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hepatitis C Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis C Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C Virus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C Virus Infection drugs.

Hepatitis C Virus Infection Report Insights

• Hepatitis C Virus Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatitis C Virus Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatitis C Virus Infection drugs?
• How many Hepatitis C Virus Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C Virus Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C Virus Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis C Virus Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sunshine Lake Pharma Co., Ltd.
• GeneCure Biotechnologies
• Biotron
• Cocrystal Pharma
• Genecure Biotechnologies Preclinical
• iQur
• Atea Pharmaceutical
• Dongguan HEC TaiGen Biopharmaceuticals
• Nanjing Sanhome Pharmaceutical

Key Products

• HEC74647PA+HEC110114
• HCVax
• BIT 225
• CC-31244
• Prophylactic HCV vaccine
• iQur Research programme
• Bemnifosbuvir + Ruzasvir
• TG-2349
• SH229